William Rastetter

Effective as of July 20, 2017, Daré Bioscience Operations, Inc. became a wholly owned subsidiary of Cerulean Pharma Inc., and Cerulean changed its name to Daré Bioscience, Inc. Rastetter now serves on the board of directors and as chair of the board of Daré Bioscience.

Rastetter serves on the board of GRAIL, Inc., a life sciences company in Menlo Park, California that focuses on early cancer detection using deep genome sequencing. Rastetter served as chair (2017-2018) and as interim CEO (2017) during a leadership transition at the company which resulted in the hiring of Jennifer Cook. GRAIL's CEO is currently Hans Bishop; the company was a spinoff of Illumina and Google.

Rastetter was also a co-founder, interim CEO and chairman of Receptos, Inc. a biopharmaceutical company which was bought by Celgene Corporation in 2015.

Rastetter served on the board of trustees of Caltech from October 28, 2015 to 2018.

Rastetter served (2014-2019) as a Member of the Advisory Council for Leerink Partners LLC (now SVB Leerink), an investment bank focusing on healthcare. Other members included David Evans Shaw, James R. Tobin, David E.I. Pyott and Francois Nader.

Rastetter was appointed to the board of directors at Regulus Therapeutics Inc. as of April 1, 2013.

Rastetter joined Fate Therapeutics, Inc. on December 14, 2011 as a director and as chair of the board. Rastetter served as the Interim CEO at Fate Therapeutics from February 2012 to October 15, 2012, when Christian Weyer became president and CEO; Scott Wolchko is Fate's current president and CEO. Rastetter has continued as chair of the board of directors.

In 2007, Rastetter cofounded Receptos, Inc., a biopharmaceutical company. Rastetter served as interim CEO of Receptos from May 2009 to December 2, 2010; and as a director and chair of the board from May 2009 to August 27, 2015. Receptos was acquired by Celgene Corporation in 2015.

Rastetter has been a Director at Neurocrine Biosciences, Inc. since February 8, 2010, and the chair of the board of Neurocrine since May 25, 2011.

Rastetter was involved in the funding of Cerulean Pharma, Inc. as early as 2009. He became a Director of Cerulean Pharma in January 2014. He served as its Lead Independent Director from April 2014 to June 2016, and as chair of the board at Cerulean Pharma Inc. from June 2016 to July 2017.

Rastetter was a partner at the venture capital firm Venrock from 2006 until February 2013.

In 2003, Idec Pharmaceuticals merged with Biogen to form the third largest biotech firm in the United States. Following the merger, Rastetter became the executive chair of the new company, Biogen IDEC (2003–2005).

Rastetter serves as an adviser to Illumina Ventures, which focuses its investments in start-up companies driven by genomics and next generation sequencing technologies. Rastetter served on the board of directors of Illumina, Inc. from 1998 to 2016, and as the non-executive chair of the Board of Directors of Illumina, Inc. from 2005 to 2016.

While at IDEC, Rastetter was a co-inventor of Rituxan, which it co-marketed with Genentech. Rituxan was the first monoclonal antibody (MAB) to be approved by the FDA (1997) for the treatment of cancer.

Between 1986 and 2003, Rastetter held positions as President, Chief Executive Officer, Chief Financial Officer and director at IDEC Pharmaceuticals. At IDEC, Rastetter was a co-inventor of and developed Rituxan, the first monoclonal antibody (MAB) to be approved by the U.S. FDA for cancer therapy. In 2003, Idec merged with Biogen to form the third largest biotech firm in the United States. Rastetter was Executive Chair of the new company, Biogen IDEC, from 2003 to 2005.

Rastetter joined IDEC Pharmaceuticals, which was founded in 1985, as of December 1986, shortly after funding of the Series A venture round. In addition to being a director (1986-2003) and chair (1996-2003), he served as chief financial officer (1988–1993), and president and chief executive officer from 1986 to 2003.

William Rastetter was married to illustrator Lucy Sands Dillon on August 21, 1982. He moved to Rancho Santa Fe in 1987.

Rastetter joined Genentech Inc. in 1982 as a scientist, and directed its Biocatalysts and Chemical Sciences Groups from 1982 to 1984. From 1984 to 1986, he served as Director of Corporate Ventures at Genentech.

Rastetter was an associate professor of chemistry at MIT. He held the Firmenich Endowed Chair (1979–1981) and an Alfred P. Sloan Fellowship (1980–1982).

Rastetter graduated from high school in Bethesda, Maryland. He went to MIT for his undergraduate work, receiving a bachelor of science (SB) in chemistry in 1971. He earned a master's (MA) in 1972 and a doctoral degree (PhD) in organic chemistry in 1975 from Harvard University. His advisor at Harvard was Nobel Prize winner Robert Burns Woodward. While at Harvard, Rastetter taught undergraduate classes.

William H. (aka Bill) Rastetter (born 1948), a scientist, entrepreneur and venture capitalist, is the chair of Neurocrine Biosciences, of Fate Therapeutics, and of Daré Bioscience, Inc. in San Diego, California. He is a founding board member and investor in GRAIL, Inc. in Menlo Park, California, and served for a period as the company's interim CEO (2017) and chair (2017-2018). Rastetter is also a director of Regulus Therapeutics. He was a partner in the venture firm Venrock (2006-2013), and a trustee at Caltech (2015-2018). He has served as a director (1998-2016) and as chair of Illumina (2005-2016). He advised SVB Leerink (2014-2019) and currently advises Illumina Ventures (since 2016).

William Harry Rastetter was born in 1948 in Panama to Richard William Rastetter and Margaret Van Oot Rastetter of Williamsburg, Va. Richard William Rastetter was a commander in the United States Navy and later worked for the State Department. As a result, the family lived in several countries, including Panama, Brazil, and Costa Rica. Rastetter is bilingual in English and Spanish. Rastetter's mother, Margaret Van Oot Rastetter, was an oil painter. She encouraged his interest in the sciences.